July 2019—Myriad Genetics announced a study published in Breast Cancer Research and Treatment (Sestak I, et al. 2019;176[2]:377–386) found that the EndoPredict test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy.
The study evaluated the ability of the EndoPredict test to predict chemotherapy benefit based on the analysis of the 10-year distant recurrence rate in women with ER-positive, HER2-negative breast cancer who received five years of endocrine therapy alone or in combination with chemotherapy. Data from 3,746 women (2,630 on endocrine therapy alone and 1,116 on endocrine therapy plus chemotherapy) were included in the analysis. The study found that women with a high EndoPredict score (i.e. > 3.3) and who received ET plus chemotherapy had significantly lower 10-year recurrence risk than those on ET alone. There were no significant differences between ET plus chemotherapy and ET for patients with low EndoPredict scores, suggesting these women are unlikely to benefit from adjuvant chemotherapy.
Myriad Genetics, 801-584-3600